{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,16]],"date-time":"2026-05-16T08:27:24Z","timestamp":1778920044160,"version":"3.51.4"},"reference-count":0,"publisher":"S. Karger AG","license":[{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"},{"start":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T00:00:00Z","timestamp":1502409600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/karger.com\/pages\/terms-and-conditions"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dev Pharmacol Ther"],"abstract":"<jats:p>Eight children excessively exposed to benzodiazepines (BZD) in utero are\ndescribed. Five of the 8 mothers admitted regular use of BZD and in 3 mothers, stored serum\nfrom early pregnancy could be analysed and found positive for BZD and its metabolite. All\nthe children had similar dysmorphic features, in addition, 1 child had aplasia of one kidney\nan 2 had cleft palate. At follow-up 2 children had become microc\u00e9phalie. 2 were severely\nmentally retarded, 5 had a mild mental retardation and only 1 was of normal intelligence. In a\ncase-control study, 4 neonatal diagnoses of congenital malformations, in our experience\ncharacteristic of fetal BZD exposure, were chosen as inclusion criteria. In 8 of 18 cases, blood\nsamples from early pregnancy were positive for BZD as compared to 2 of 60 control samples.\nAn association between BZD-positive serum tests and the particular diagnoses could be\ndemonstrated (p = 0.00006).<\/jats:p>","DOI":"10.1159\/000457644","type":"journal-article","created":{"date-parts":[[2017,8,11]],"date-time":"2017-08-11T17:09:03Z","timestamp":1502471343000},"page":"186-188","source":"Crossref","is-referenced-by-count":6,"title":["Clinical Observations in Children after Prenatal\nBenzodiazepine Exposure"],"prefix":"10.1159","author":[{"given":"Liv","family":"Laegreid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2017,8,11]]},"container-title":["Developmental Pharmacology and Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/karger.com\/article-pdf\/doi\/10.1159\/000457644","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,22]],"date-time":"2026-04-22T08:35:17Z","timestamp":1776846917000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000457644"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8,11]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1159\/000457644","archive":["Portico"],"relation":{},"ISSN":["0379-8305","2504-2505"],"issn-type":[{"value":"0379-8305","type":"print"},{"value":"2504-2505","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,8,11]]}}}